PTO/SB/21 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Onder the 7 aberwork Ne	eduction Act of 1995, no berson	Application Number	10/556,227		inless it d	displays a valid OMB control number.
TRANSI	MITTAI	Filing Date	November			
FOI		First Named Inventor	 			
10	IXIVI	Art Unit	Not Known	David Laurent, et. al.		
		Examiner Name	 			
(to be used for all correspond	ondence after initial filing)	Attorney Docket Number	Not Known			
Total Number of Pages in T	This Submission 7	Attorney bocket Number	101055-1P	US		<i>_</i>
	ENC	LOSURES (Check al	i that apply	·)		
Extension of Time Express Abandonn Information Disclos Certified Copy of P Document(s) Reply to Missing P Incomplete Applica Reply to M	eclaration(s) Request ment Request sure Statement Priority Rema	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocatic Change of Correspondence Terminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table on Carks	Address	Interr	Appea of App Appea (Appea Proprie Status Other below) Referen	Enclosure(s) (please Identify :
	SIGNATURE	OF APPLICANT, ATTO	DRNEY, C	R AGI	ENT	
Firm Name AstraZe	neca Pharmaceuticals (ad	dress associated with Custon	ner No. 224	66)		
Signature K	ner D. Ko	ndead				
Printed name Karen H	Printed name Karen H. Kondrad					
Date July 17,	Date July 17, 2006 Reg. No. 38,212					
CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with						
the date shown below:	class mail in an envelope a	adressed to: Commissioner f	or Patents, I	P.O. Box	1450,	Alexandria, VA 22313-1450 on
Signature	Marie Th	V. Grelock	<u> </u>			
Typed or printed name	Marie M. Greloch				Date	July 17, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/556,227	Applicant: David Laurent, et. al.
371 Filing Date: November 9, 2005	Attorney Docket No.: 101055-1P US
Examiner: Not Known	Group Art Unit : Not Known
Customer No.: 22466	Confirmation No.: Not Known
Title: Azaindole Compounds as Kinase I	nhibitors

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on July 17, 2006

Signature

Marie M. Greloch

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir,

Applicants submit herewith a list of patents and publications pursuant to the duty to disclose in accordance with 37 C.F.R. § 1.56.

In accordance with 37 C.F.R. § 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

In accordance with the U.S. Patent Office's partial waiver of the requirement under 37 C.F.R. 1.98(a)(2)(i), only copies of the foreign patent documents and non-patent publications are enclosed.

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed:

	within three	e (3) months of the filing date of a national application other	than a
	continued	prosecution application under 37 C.F.R. 1.53(d), or within thr	ee (3) months
	of the date	of entry of the national stage as set forth in 37 C.F.R. 1.49	91 in an
	internation	al application, or before the mailing of the first Office Action	on the
	merits, or t	pefore the mailing of a first Office Action after the filing of a	request for
	continued	examination under 37 C.F.R. 1.114; or	
☐ (2)		eriod defined in (1) but before the mailing date of a final Acti Allowance under 37 C.F.R. 1.311, and	on or a
		the requisite Statement is below, OR	
		the Commissioner is hereby authorized to charge the recunder 37 C.F.R. 1.17(p), namely \$180.00 to deposit accompanies, referencing Attorney Docket No.	•
(3)	after the m	nailing date of a final Action or Notice of Allowance but bef	ore the
	payment o	f the Issue Fee, AND	
		the requisite Statement is below, AND	
		the Commissioner is hereby authorized to charge the rec	quisite fee
		under 37 C.F.R. 1.17(p), namely \$180.00 to deposit according	ount No.
		, referencing Attorney Docket No.	, or

It is respectfully requested that each of the patents and publications listed on the attached Form SB08, and other information contained herein, be considered by the Examiner and made of record in this application

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 22,466, referencing Attorney Docket No. 101055-1P US.

STATEMENT

As required under 37 C.F.R. 1.97(e), Applicant(s), through the undersigned, hereby state either that:

- (1) Each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application **not more than three months** prior to the filing of the Information Disclosure Statement; or
- [2] No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to **any individual** designated in 37 C.F.R. 1.56(c) **more than three months** prior to the filing of the Information Disclosure Statement.

Respectfully submitted,

Name: Karen H. Kondrad Dated: July 17, 2006

Reg. No.: 38,212

Phone No.: 302.886.8975

Global Intellectual Property, Patents,

AstraZeneca,

1800 Concord Pike,

Wilmington,

DE-19850-5437

Enclosures: Form SB08A Form SB08B Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO Application Number 10/556,227 Filing Date November 9, 2005 INFORMATION DISCLOSURE First Named Inventor David Laurent, et al STATEMENT BY APPLICANT Art Unit Not Known (Use as many sheets as necessary) Examiner Name Not Known Sheet 1 of |2 Attorney Docket Number 101055-1P US

Examiner	Cite	Decument Number		DOCUMENTS	1 5 61 11
Initials*	No.1	Document Number Number-Kind Code ^{2 (5 known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	^{US-} 6,686,374B1	02-03-2004	Louise Edwards, et al.	
	A2	^{US-} 5,338,849A	08-16-1994	Didier Festal, et al.	
	АЗ	^{US-} 5,389,509A	02-14-1995	Joe E. Maskasky	
		US-			•
		US-			

		FORE	IGN PATENT DOCU	MENTS		
Examiner Cite Initials* No.1		Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	T
		Country Code ^{3 -} Number ^{4 -} Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T ⁶
	A4	WO 2004/16609 A1	02-26-2004	Aadal Nielsen, et. al.		
	A5	WO 01/47922 A2	07-05-2001	Paul Joseph Cox, et. al.		
	A6	WO 00/00202	01-06-2000	Faith M. Uckun		
	A7	WO 99/65909	12-23-1999	Todd A. Blumenkopf, et al		
	A8	WO 00/18761	04-06-2000	Allan Wissner, et. al.		
	A9	WO 98/43960	10-08-1998	Allan Wissner, et. al.		

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

101055-1P US

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO Application Number 10/556,227 Filing Date November 9, 2005 INFORMATION DISCLOSURE First Named Inventor David Laurent, et al STATEMENT BY APPLICANT Art Unit Not Known (Use as many sheets as necessary) Examiner Name Not Known

Attorney Docket Number

Sheet 2

			U. S. PATENT D	OCUMENTS	
Examiner Initials*	Cite No.1	Cite Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
		Number-Kind Code ^{2 (# known)}	<u>'</u>		Figures Appear
		US-			
		US-		4	
		US-			
		US-	<u> </u>		
		US-			
	ļ .	US-			
		US-			
		US-			
	<u> </u>	US-			
		US-			
	<u> </u>	US-			
		US-			
	† " "	US-			
	1	US-			
	1	US-			
	 	US-	 		-

		FORE	IGN PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1				Pages, Columns, Lines, Where Relevant Passages	
		Country Code ^{3 -} Number ^{4 -} Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T ⁶
	A10	WO 02/092571	11-21-2002	Joakim Larsson, et. al.		
	ļ					<u> </u>
	ļ					L
						<u></u>

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Include the communication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known
	Application Number	10/556,227
INFORMATION DISCLOSURE	Filing Date	November 9, 2005
STATEMENT BY APPLICANT	First Named Inventor	David Laurent, et. al.
(Use as many sheets as necessary)	Art Unit	Not Known
(out do many sheets as necessary)	Examiner Name	Not Known
Sheet 1 of 1	Attorney Docket Number	101055-1P US

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A11	Boschelli, Diane H., et. al., "Synthesis and Src Kinase Inhibitory 3-Quinolinecarbonitriles", J. Med. Chem. 2001, 44, pages 822-833	
	A12	Elsie A. Sudbeck, et. al., "Structure-based Desige of Specific Antileukemic Agents", Clinical Cancer Research, Vol. 5, June 1999, pages 1569-1582	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Title: Azaindole Compounds as Kinase Inhibitors Inventor(s): David Laurent, et. al. Date Filed: November 9, 2005

By date-stamping and returning this card the USPTO acknowledges the receipt of:

Transmittal Form (1 page)
 Information Disclosure Statement (3 pages)
 Form PTO/SB/08A (2 pages)
 Form PTO/SB/08B (1 page)
 9 References
 International Search Report
 Return Receipt Postcard

Mailed: July 17, 2006 Docket No.: 101055-1P US KKO/mmg

NO POSTAGE NECESSARY IF MAILED IN THE UNITED STATES

BUSINESS REPLY MAIL

FIRST-CLASS MAIL PERMIT NO. 250 WILMINGTON, DE

POSTAGE WILL BE PAID BY ADDRESSEE

PATENT AND TRADEMARK ADMINISTRATOR GLOBAL INTELLECTUAL PROPERTY R & D BUILDING ASTRAZENECA